Report Highlights
The global market for drug-device combinations is expected to grow from $129.4 billion in 2024 and is projected to reach $199.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 9.1% during the forecast period of 2024 to 2029.
Report Includes
- 40 data tables and 43 additional tables
- An analysis of the global markets for drug-device combination (DDC) products and biological devices
- Analyses of global market trends, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
- Estimate of the current market size and revenue prospects of the global market, along with a market share analysis by product type, application (disease area), end-user, and region
- Facts and figures pertaining to the market dynamics, current and emerging technologies, regulations, prospects, product recalls, pipeline products, and the expected impact of macroeconomic factors
- Review of the industry supply chain, using the Porter’s Five Forces model, to analyze the prevailing micro- and macro environmental factors
- Overview of ESG developments and sustainability trends in the industry, with a focus on consumer attitudes, companies’ ESG score rankings and their ESG practices
- An analysis of the industry structure, including companies’ market shares, alliances, M&A activity and venture funding outlook
- Profiles of the leading market players, including Medtronic, Boston Scientific Corp., Stryker, Abbott, and BD
Report Scope
The global market for drug-device combination is a rapidly expanding healthcare industry segment, encompassing products that integrate pharmaceutical drugs with medical devices to enhance treatment efficacy and patient convenience. The current report provides a comprehensive introduction and delves into the market for drug-device combinations. It examines market trends of these products, utilizing data from 2021, estimates for 2024 and projections of compound annual growth rates spanning 2024 through 2029 (forecast period) and regional markets of the drug-device combination product market. This report highlights drug-device combinations’ current and future market potential and a detailed competitive environment analysis. It covers the regulatory scenario, drivers, restraints, challenges, opportunities, emerging technologies and sustainability in drug-device combinations. The report also covers market projections for 2029 and the market share for key market players. The report informs all market players, potential entrants, government agencies and other interested parties. It covers geographic regions in detail, so companies interested in expanding their geographic reach will also find this study helpful.
Report Synopsis
| Report Metrics | Details | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2023 | ||||||||||
| Forecast period considered | 2024-2029 | ||||||||||
| Base year market size | $119.4 billion | ||||||||||
| Market size forecast | $199.8 billion | ||||||||||
| Growth rate | CAGR of 9.1% for the forecast period of 2024-2029 | ||||||||||
| Units considered | $ Millions | ||||||||||
| Segments covered | Product Type, Application, and Region | ||||||||||
| Regions covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) | ||||||||||
| Countries covered | China, India, Japan, U.S., Canada, Mexico, Germany, U.K., Italy, Spain, and France | ||||||||||
| Key Market Drivers |
|
||||||||||
| Companies studied |
|
Frequently Asked Questions (FAQs)
- Increase prevalence of chronic diseases.
- Wide Range of Potential Applications of Combinations Products.
- Empowering Patients: Integrating Homecare Trends with Drug Delivery Advancements.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Consulting Editor’s Credentials
Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.
Report Highlights
The global drug-device combination products market should reach $149 billion by 2026 from $103.5 billion in 2021 at a compound annual growth rate (CAGR) of 7.6% for the forecast period of 2021 to 2026.
Report Includes
- 47 tables
- An overview of the global market for drug-device combination products
- Estimation of the market size and analyses of global market trends, with data from 2019 to 2020, 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Characterization and quantification of market potential for drug-device combinations by type, application, and region
- Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market trends, market size, and market forecast
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis
- Company profiles of major players, including Abbott, Boston Scientific Corp., Johnson & Johnson Services Inc. and Sanofi S.A.
Report Highlights
The sales of drug-device combination products reached $21.4 billion in 2013 and $22 billion in 2014. This market is expected to grow to $31 billion in 2019, with a compound annual growth rate (CAGR) of 7.1% from 2014 to 2019.
Report Includes
- An overview of the global market for drug-device combinations.
- Analyses of global market trends, with data from 2013 and 2014, and projections of CAGRs through 2019.
- Detailed coverage of such product categories as drug-eluting stents (DES), drug-eluting beads (DEB), antimicrobial catheters, antibiotic-loaded bone cements, glass ionomer cements, bone graft substitutes, antibacterial-releasing dental restorative materials, biologic wound care products such as collagen-based dressings as therapeutic agents for wound healing, drug-device combination products for ocular applications, and photodynamic therapy.
- Detailed patent analysis and research and development updates.
- Comprehensive company profiles of major players.
Report Highlights
The market for global drug device combination products was valued at $18.5 billion in 2011 and should reach $19 billion in 2012. Total market value is expected to reach $30.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.9%.
Report Includes
- An overview of the global market for drug-device combinations
- Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Detailed coverage of such product categories as drug-eluting stents (DES), drug-eluting beads (DEB), antimicrobial catheters, antibiotic-loaded bone cements, glass ionomer cements, bone graft substitutes, antibacterial-releasing dental-restorative materials, biologic wound-care products such as collagen-based dressings as therapeutic agents for wound-healing, drug-device combination products for ocular applications, and photodynamic therapy
- Identification of current and future technologies, products, market segments/end markets, and government and regulatory agencies
- Discussion of participating companies in light of technological strengths and weaknesses, relative market shares, marketing strengths, and innovative marketing practices
- Detailed patent analysis and research and development updates
- Comprehensive company profiles of major players.
Report Highlights
- Overall sales of drug device combination products were $12 billion in 2008 and $13.7 billion in 2009. This is projected to reach $27 billion in 2014 at a compound annual growth rate (CAGR) of 14.5%
- Sales in coronary stents Products were nearly $4.4 billion in 2008 and $4.8 billion in 2009. This market is projected to reach $7.4 billion in 2014, for a 5-year CAGR of 9%.
- Photodynamic therapies market was $1.3 billion in 2008, which increased slightly in 2009 to $1.5 billion. This market is projected to reach approx $2.6 billion in 2014, for a 5-year CAGR of 11.6%.
Report Highlights
-
The total market for drug-device combinations worldwide was valued at $5.4 billion in 2004 and is expected to rise at an average annual growth rate (AAGR) of 13.6% to $11.5 billion in 2010.
-
The star category is drug-eluting stents that will continue to show average annual growth of 11.5%. This will result in the market doubling to $8 billion in 2010.
-
With the exception of bone graft substitutes and antibiotic bone cements, all categories will show double-digit growth.
-
The U.S. dominates the market for drug-device combination products, mainly because the largest-selling drug-eluting stents have been enthusiastically accepted in this market and consequently are penetrating the market more quickly than in Europe.
Related Reports
Conventional and Alternative Pain Treatment Markets
The global market for conventional and alternative pain treatment is expected to grow from $96.2 billion in 2024 and is projected to reach $144.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.4% during the forecast period of 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Microelectronic Medical Implants: Products, Technologies & Opportunities
The global market for microelectronic medical implants is expected to grow from $49.0 billion in 2024 and is projected to reach $85.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.7% during the forecast period of 2024 to 2029.
Health and Medical Insurance Providers: Global Markets
The global market for health and medical insurance providers is expected to grow from $2.2 trillion in 2023 to $3.4 trillion by the end of 2028, at a compound annual growth rate (CAGR) of 8.9% during the forecast period of 2023 to 2028.
Recent Reports
Softgel Capsules: Global Markets
The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Active Pharmaceutical Ingredients: Global Markets
The global market for active pharmaceutical ingredients (APIs) is estimated to increase from $247.8 billion in 2023 to reach $347.9 billion by 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.
Global Market for Contract Research Organization (CRO) Services
The global market for contract research organization (CRO) services is expected to grow from $111.8 billion in 2024 and is projected to reach $166.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.
Global Oncology Pharmaceuticals Market
The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Direct-to-Consumer Genetic Testing: Global Markets and Technologies
The global market for DTC genetic testing is expected to grow from $2.3 billion in 2024 and is projected to reach $3.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.0% during the forecast period of 2024 to 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More